Illumina's Q3 Revenues Soar 54 Percent; Avantome Purchase Impacts Bottom Line | GenomeWeb
NEW YORK (GenomeWeb News) - Illumina today reported a 54 percent boost in third-quarter revenue as a profit swung to a loss due to charges associated with its acquisition of sequencing startup Avantome.
For the quarter ended Sept. 30, Illumina reported revenues of $150.3 million, a 54 percent increase over $97.5 million in the third quarter of 2007 and its 29th consecutive quarter of revenue growth.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.